Cargando…
Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, mos...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649879/ https://www.ncbi.nlm.nih.gov/pubmed/29147383 http://dx.doi.org/10.14740/wjon779w |
_version_ | 1783272624567091200 |
---|---|
author | Kapur, Sakshi Xiao, Han Zakowski, Maureen F. Hameed, Meera R. Levin, Miles B. |
author_facet | Kapur, Sakshi Xiao, Han Zakowski, Maureen F. Hameed, Meera R. Levin, Miles B. |
author_sort | Kapur, Sakshi |
collection | PubMed |
description | Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, most patients are able to tolerate the recommended dose of 140 mg daily. Surgical resection is the primary treatment for medullary thyroid carcinoma. Patients with metastatic disease, who are not candidates for surgery, are considered candidates for systemic therapy. However, systemic chemotherapy has a limited role in metastatic disease. Our paper highlights not only the malignant potential of a medullary thyroid carcinoma, but also the role of cabozantinib in patients with progressive metastatic disease. We report two cases of patients with progressive metastatic medullary thyroid carcinoma (involving lung, lymph nodes, liver, pancreas, brain and spine) who responded well to therapy with cabozantinib. |
format | Online Article Text |
id | pubmed-5649879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56498792017-11-16 Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature Kapur, Sakshi Xiao, Han Zakowski, Maureen F. Hameed, Meera R. Levin, Miles B. World J Oncol Case Report Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, most patients are able to tolerate the recommended dose of 140 mg daily. Surgical resection is the primary treatment for medullary thyroid carcinoma. Patients with metastatic disease, who are not candidates for surgery, are considered candidates for systemic therapy. However, systemic chemotherapy has a limited role in metastatic disease. Our paper highlights not only the malignant potential of a medullary thyroid carcinoma, but also the role of cabozantinib in patients with progressive metastatic disease. We report two cases of patients with progressive metastatic medullary thyroid carcinoma (involving lung, lymph nodes, liver, pancreas, brain and spine) who responded well to therapy with cabozantinib. Elmer Press 2014-04 2014-05-06 /pmc/articles/PMC5649879/ /pubmed/29147383 http://dx.doi.org/10.14740/wjon779w Text en Copyright 2014, Kapur et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Kapur, Sakshi Xiao, Han Zakowski, Maureen F. Hameed, Meera R. Levin, Miles B. Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature |
title | Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature |
title_full | Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature |
title_fullStr | Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature |
title_full_unstemmed | Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature |
title_short | Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature |
title_sort | metastatic medullary thyroid carcinoma and cabozantinib: case series and review of literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649879/ https://www.ncbi.nlm.nih.gov/pubmed/29147383 http://dx.doi.org/10.14740/wjon779w |
work_keys_str_mv | AT kapursakshi metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature AT xiaohan metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature AT zakowskimaureenf metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature AT hameedmeerar metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature AT levinmilesb metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature |